Actively Recruiting
Phase 2 Trial of FT819 Cell Therapy for Moderate-to-Severe Refractory Lupus Nephritis in Systemic Lupus Erythematosus
Led by Fate Therapeutics · Updated on 2026-09-14
53
Participants Needed
12
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of FT819, a treatment made of allogeneic T cells expressing a CD19-targeted CAR, for people with moderate-to-severe systemic lupus erythematosus SLE who have lupus nephritis LN that has not responded to at least two prior immunosuppressive treatments. This phase 2, open-label, single-arm trial focuses on participants aged 12 to 70 with biopsy-proven Class III or IV LN and active disease. The study aims to measure how many participants achieve complete renal response at 26 weeks. Participants will first undergo a screening period lasting up to 28 days. After screening, they will receive bendamustine treatment followed by a single intravenous infusion of FT819. The study will include efficacy, safety, and exploratory assessments at scheduled timepoints through 24 months of post-treatment follow-up. After this, participants will be monitored for safety and survival for up to 15 years in a long-term follow-up phase. Throughout the study, researchers will assess lupus nephritis activity using standard measures, including complete and partial renal responses, and clinician-reported outcomes such as SLEDAI-2K, BILAG, and PGA scores. Safety and disease activity evaluations will take place at predefined visits. The total duration of participation includes multiple assessments during the first two years and extended long-term monitoring up to 15 years to observe ongoing effects and survival.
CONDITIONS
Brief Title
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Research Team
F
Fate Clinical Trials
N
Natalie Shiff, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here